Option Therapeutics, a Phase 2 liver disease biotech spun out of BioVie, filed on Monday with the SEC to raise up to $25 million in an initial public offering.
The Carson City, NV-based company plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. The company did not disclose the number of shares outstanding.
The company focuses on the development of therapeutic candidates for the treatment of serious and life-threatening liver diseases. The lead product, BIV201, is being evaluated for the treatment of complications associated with advanced liver cirrhosis and is patent-pending in U.S., China, Japan, Chile, and India. Option Therapeutics has yet to generate revenue.
Option Therapeutics was founded in 2025 and plans to list on the NYSE American under the symbol OPTN. ThinkEquity is the sole bookrunner on the deal.
